Skip to main content
CGC
NASDAQ Life Sciences

Canopy Growth Seeks Shareholder Nod for Reverse Split, Advance Notice By-Law, and Incentive Plan Renewal Amid Restatement Fallout

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.955
Mkt Cap
$417.909M
52W Low
$0.844
52W High
$2.38
52W Position info
13% above low
Off High info
60% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

CGC is trading near its 52-week low of $0.844 (13% above the low) on light trading volume (0.2× avg).

Summary

Canopy Growth's proxy seeks approval for a reverse stock split to maintain its Nasdaq listing, alongside an advance notice by-law and incentive plan renewal. The filing discloses a recent management cease trade order, a material weakness in internal controls, and a restatement of prior financials.


Key Events · Corporate Governance and Compliance · CGC

  • Reverse Stock Split Proposed

    To lift the stock price above $1.00 and preserve its Nasdaq listing, the board seeks authority to consolidate shares at a ratio between 1-for-5 and 1-for-15. If approved, the exact ratio will be set by the board within 12 months.

  • Management Cease Trade Order Disclosed

    On May 28, 2026, the Ontario Securities Commission issued a management cease trade order against CEO Luc Mongeau and CFO Thomas Stewart following a restatement of prior financials. The order was lifted on June 16, 2026, after the restated 10-K was filed.

  • Material Weakness and Restatement Acknowledged

    A non-cash accounting error related to warrant classification forced the company to restate its fiscal 2024 and 2025 financials. A material weakness in internal controls was identified, and the company disclosed a default by its major U.S. investment, Acreage Holdings.

  • Advance Notice By-Law and Incentive Plan Renewal

    Shareholders will vote on an advance notice by-law for director nominations and the renewal of the Omnibus Incentive Plan. Though standard governance items, they carry added weight given the company's recent control failures.


Analysis · CGC · Life Sciences

Canopy Growth's preliminary proxy paints a picture of a company under severe strain. To stave off a Nasdaq delisting—with shares languishing near $0.95—the board is asking shareholders to authorize a reverse stock split at a ratio between 1-for-5 and 1-for-15. The filing also reveals that a management cease trade order was imposed on the CEO and CFO in May 2026 (lifted the following month), a material weakness exists in internal controls, and two years of financials have been restated. These are serious governance red flags. While the advance notice by-law and incentive plan renewal are routine, the reverse split and the frank admission of recent regulatory and accounting failures signal a company fighting for its listing and its credibility.

At the time of this filing, CGC was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $417.9M. The 52-week trading range was $0.84 to $2.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CGC - Latest Insights

CGC
Jul 17, 2026, 4:25 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.9549
Real-time Price: $0.9549 info
Change: $0 (0%) info
Market Cap: $417.909M info
CGC
Jun 15, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.965
Real-time Price: $0.9549 info
Change: -$0.0101 (-1%) info
Market Cap: $417.909M info
CGC
Jun 15, 2026, 6:46 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.01
Real-time Price: $0.9549 info
Change: -$0.0551 (-5%) info
Market Cap: $417.909M info
CGC
May 15, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.03
Real-time Price: $0.9549 info
Change: -$0.0751 (-7%) info
Market Cap: $417.909M info
CGC
Mar 16, 2026, 7:59 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $0.9549 info
Change: -$0.0751 (-7%) info
Market Cap: $417.909M info
CGC
Feb 13, 2026, 4:08 PM EST
Filing Type: 424B3
Importance Score:
7
Price at Filing: $1.09
Real-time Price: $0.9549 info
Change: -$0.1351 (-12%) info
Market Cap: $417.909M info
CGC
Feb 06, 2026, 4:15 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.11
Real-time Price: $0.9549 info
Change: -$0.1551 (-14%) info
Market Cap: $417.909M info
CGC
Feb 06, 2026, 6:45 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.15
Real-time Price: $0.9549 info
Change: -$0.1951 (-17%) info
Market Cap: $417.909M info
CGC
Jan 15, 2026, 4:10 PM EST
Filing Type: 424B3
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $0.9549 info
Change: -$0.2751 (-22%) info
Market Cap: $417.909M info
CGC
Jan 09, 2026, 4:05 PM EST
Filing Type: S-3
Importance Score:
9
Price at Filing: $1.24
Real-time Price: $0.9549 info
Change: -$0.285 (-23%) info
Market Cap: $417.909M info